Skip to main content
. 2019 Jul 18;182(3):605–617. doi: 10.1111/bjd.18232

Figure 1.

Figure 1

Integrated design of the reSURFACE 1 and reSURFACE 2 trials. Differences in design for reSURFACE 2 vs. reSURFACE 1 are shown in turquoise colour. Groups of interest for efficacy analyses are marked in bold. D/C, discontinued; N/A, not applicable; NR, nonresponders [< 50% improvement in Psoriasis Area and Severity Index (PASI 50)]; PR, partial responders (PASI 50–75); R, responders (PASI ≥ 75).